The Hain Celestial Group, Inc. (HAIN) AI Stock Analysis

NASDAQ: HAINAI research summary: business, growth, valuation, analysts, bull and bear case.

HAIN AI stock analysis summary

AI Research

The Hain Celestial Group, Inc. (HAIN) manufactures and distributes organic and natural food, beverage, and personal care products globally. The company faces persistent top-line headwinds, with FY2026 revenue falling 13.2% to $1.35B and net income recording a loss of -$304.9M. Leverage remains high, with net debt standing at $551.4M against a market capitalization of $21.5M.

Market cap
$21.5M
Revenue (TTM)
$1.35B
P/E
—
fwd 17.9x
1Y return
-82.0%
S&P 500 16.8%
Avg. target
$1.43
497.2% vs last close

Bull case

  • Free cash flow improved to $57.7M in FY2026, recovering from -$3.2M in FY2025.
  • The analyst consensus mean price target of $1.43 indicates a 497.2% premium over the closing price of $0.24.
  • Analyst estimates expect EPS losses to narrow from -$0.17 in FY2026 to -$0.04 in the fiscal year ending June 30, 2027.

Bear case

  • Revenue fell 13.2% in FY2026 to $1.35B, accompanied by a net loss of -$304.9M.
  • Total debt of $609.5M exceeds the cash balance of $58.1M, creating a low current ratio of 0.50.
  • The stock has beaten earnings expectations 0 times over the last 4 quarters and declined 82.0% over the trailing 1-year period.

What Hain Celestial does

The Hain Celestial Group, Inc. is a manufacturer, marketer, and distributor of organic and natural products across the United States, United Kingdom, and international markets. Operating through North America and International segments, the company offers infant and toddler food, plant-based beverages, frozen desserts, cooking oils, soups, yogurts, condiments, and snacks. Its personal care line includes brands like Alba Botanica, Avalon Organics, Earth's Best, JASON, Live Clean, and Queen Helene. Pantry items, including herbal teas, nut butters, and broths, are marketed under brands such as Celestial Seasonings, Imagine broths, MaraNatha, and Spectrum across approximately 80 countries.

Growth and profitability

HAIN has experienced continuous annual revenue contractions, resulting in a 5-year revenue CAGR of -7.2% from FY2021 to FY2026. Annual revenue dropped from $1.89B in FY2022 to $1.35B in FY2026, including a 13.2% decline in FY2026. Over the same timeframe, gross margin contracted from 22.6% to 20.1%, while operating margin ended FY2026 at -15.0%. Net losses were recorded in each of the last four fiscal years, ending FY2026 with net income of -$304.9M and an EPS of -$0.17. For the latest quarter ended June 30, 2026, quarterly revenue fell 27.6% year-over-year, and quarterly earnings decreased 63.5%.

HAIN income statement →

Balance sheet and cash flow

As of June 30, 2026, HAIN held $58.1M in cash and short-term investments against $609.5M in total debt, leading to net debt of $551.4M. The company's current ratio was 0.50, and debt-to-equity stood at 3.94 against shareholders' equity of $154.8M. For FY2026, operating cash flow was $78.3M and capital expenditures were $20.6M, which yielded $57.7M in free cash flow. Over the past five years, the company's share count decreased 4.0%.

HAIN balance sheet →

Valuation and performance

At a share price of $0.24, HAIN has a market cap of $21.5M and an enterprise value of $601.9M. The stock trades at a forward P/E of 17.9x, which is above the median of its US-listed Consumer Defensive peers of 14.3x. Its EV-to-EBITDA stands at 68.9x compared to the peer median of 11.7x, while its price-to-book ratio is 0.3x. Over the 1-year period, HAIN shares fell 82.0%, whereas the S&P 500 (SPY) gained 16.8%. Over five years, HAIN shares dropped 99.5% against an 83.0% gain for the index.

HAIN key metrics →

What analysts expect

Wall Street coverage includes 3 analysts: 1 Buy, 1 Hold, and 1 Sell. The mean price target is $1.43, which sits 497.2% above the last close of $0.24. For the current fiscal year ending June 30, 2027, consensus estimates forecast an EPS of -$0.04 and revenue of $1.13B. For the following fiscal year, 2 analysts project an EPS of -$0.00 and revenue of $1.13B, reflecting revenue growth of 0.6%. The company beat EPS estimates in 0 of the last 4 quarters, and the next earnings date is November 6, 2026.

HAIN forecast and price target →

Key risks and what to watch

  • Liquidity remains strained with a current ratio of 0.50 and net debt standing at $551.4M.
  • Top-line contraction accelerated with a quarterly revenue decline of 27.6% for the quarter ended June 30, 2026.
  • Profitability is negative, evidenced by a trailing twelve month return on equity of -96.8% and net margin of -22.5% in FY2026.

AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer

About this HAIN AI stock analysis

This page is an AI-written research summary of The Hain Celestial Group, Inc. (HAIN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HAIN income statement, HAIN balance sheet, HAIN key metrics, HAIN analyst forecast, HAIN chart. See the HAIN stock overview for the latest quote and news.

HAIN AI stock analysis FAQ

Does The Hain Celestial Group pay a dividend?

No, the company does not currently pay a dividend.

What is HAIN's net debt position?

As of June 30, 2026, the company held $58.1M in cash and short-term investments and $609.5M in total debt, resulting in net debt of $551.4M.

When is the next earnings report for HAIN?

The next earnings date is scheduled for November 6, 2026.

What do analysts project for HAIN's revenue in the current fiscal year?

Analysts estimate revenue of $1.13B for the fiscal year ending June 30, 2027.

More Consumer Defensive AI stock analysis